He patient group. This observation thus mandates special attention to the gender variable as a potential confounder in subsequent group comparisons. Status as a de novo PD patient or the use of antidepressant medications had no significant impact on any of the measured cytokines (data not shown). Twenty-two PD patients reported dyskinesias at the time of the blood sampling. These patients did not differ significantly in any of the measured cytokines compared to theEvaluation of Non-motor SymptomsThe study participants were asked to complete the following surveys during 
their visit: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT) [20], Hospital Anxiety and Depression Scale (HAD) (including subscales for symptoms of depression as well as anxiety) [21], and Scales for Outcomes in PD-Sleep (SCOPA-S) [22]. Complete HAD anxiety Z-360 cost scores were available from 84 patients and 38 controls, complete HAD depression scores from 84 patients and 39 complete 22948146 FACIT scores from 79 patientsNon-Motor Symptoms and Serum Cytokines in PDTable 1. Demographic characteristics of patients and controls.Controls (n = 40) Sex Age (yrs, mean 6 SD) Illness duration (yrs, mean 6 SD) Hoehn and Yahr (mean 6 SD) Schwab England (mean 6 SD) UPDRS motor score (mean 6 SD) CRP (median, IQL) IL-6 (median, IQL) sIL-2R (median, IQL) TNF-a (median, IQL) HAD-anxiety (median, IQL) HAD-depression (median, IQL) FACIT-fatigue (median, IQL) SCOPA-sleep night (mean 6 SD) Asthma/allergies, n ( ) Cardiovascular disease, n ( ) Diabetes mellitus, n ( ) Osteoarthritis, n ( ) Pearson’s chi-square. Mann-Whitney. Student’s t-test. doi:10.1371/journal.pone.0047387.taPatients (n = 86) f = 35 (41 ), m = 51 64.2610.8 6.966.2 1.960.Sign .01a .75cf = 26 (65 ), m = 14 64.869.99.861.6 1.562.6 1.3, .6?.4 2.8, 2.8?.8 399.0, 332.0?43.0 (n = 39) 9.5, 7.0?1.8 1.0, .0?.0 (n = 38) .0, .0?.0 (n = 39) 51.0, 49.0?2.0 (n = 36) 3.462.7 (n = 39) 5 (13) 13 (33) 1 (3) 4 (10)90.968.0 17.3610.4 1.1, .6?.5 2.8, 2.8?.0 425.0, 332.3?39.5 10.0, 8.0?2.0 3.5, 2.0?.0 (n = 84) 2.5, 1.0?.0 (n = 84) 43.0, 36.0?8.0 (n = 79) 4.463.2 (n = 84) 10 (12) 18 (21) 3 (3) 5 (6).00c .00c .58b .02b .52b .10b .00b .00b .00b .13c .89a .16a .77a .40ab cones who did not report dyskinesias (N = 64) (purchase BTZ-043 Mann-Whitney U tests, all p-values.0.24).Non-motor Symptoms in in Patients and ControlsCompared to controls, patients with PD displayed significantly higher mean scores on the HAD depression subscale (MannWhitney U = 1080.0, p,.001), the HAD anxiety subscale (MannWhitney U = 921.0, p,.01) as well as significantly lower scores on FACIT-fatigue (Mann-Whitney U = 451.5, p,.001), thus indicating more severe symptoms in the PD group. The SCOPA-sleep night scale did not differ significantly between the two groups (Student’s t = 1.45, p..15, ns). In the entire sample there were no significant gender differences in mean scores on FACIT or the HAD subscales (Mann-Whitney U tests, all p-values .0.14), thus making gender unlikely as a confounder in these analyses. Women had, however, significantly higher mean scores on SCOPA-S compared to men (Mann-Whitney U = 1485.0, p = .04). Subsequent ANCOVA with SCOPA-S as the dependent variable and gender and diagnose as fixed factors did not reveal any significant effect of patient/control on SCOPA-S scores when the effect of gender was controlled for (p..05, ns).U = 1499.0, p = .03) and TNF-a (Mann-Whitney U = 1466.0, p = .01) ?thus making gender a potential confounder in these two comparisons. ANCOVAS wer.He patient group. This observation thus mandates special attention to the gender variable as a potential confounder in subsequent group comparisons. Status as a de novo PD patient or the use of antidepressant medications had no significant impact on any of the measured cytokines (data not shown). Twenty-two PD patients reported dyskinesias at the time of the blood sampling. These patients did not differ significantly in any of the measured cytokines compared to theEvaluation of Non-motor SymptomsThe study participants were asked to complete the following surveys during their visit: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT) [20], Hospital Anxiety and Depression Scale (HAD) (including subscales for symptoms of depression as well as anxiety) [21], and Scales for Outcomes in PD-Sleep (SCOPA-S) [22]. Complete HAD anxiety scores were available from 84 patients and 38 controls, complete HAD depression scores from 84 patients and 39 complete 22948146 FACIT scores from 79 patientsNon-Motor Symptoms and Serum Cytokines in PDTable 1. Demographic characteristics of patients and controls.Controls (n = 40) Sex Age (yrs, mean 6 SD) Illness duration (yrs, mean 6 SD) Hoehn and Yahr (mean 6 SD) Schwab England (mean 6 SD) UPDRS motor score (mean 6 SD) CRP (median, IQL) IL-6 (median, IQL) sIL-2R (median, IQL) TNF-a (median, 
IQL) HAD-anxiety (median, IQL) HAD-depression (median, IQL) FACIT-fatigue (median, IQL) SCOPA-sleep night (mean 6 SD) Asthma/allergies, n ( ) Cardiovascular disease, n ( ) Diabetes mellitus, n ( ) Osteoarthritis, n ( ) Pearson’s chi-square. Mann-Whitney. Student’s t-test. doi:10.1371/journal.pone.0047387.taPatients (n = 86) f = 35 (41 ), m = 51 64.2610.8 6.966.2 1.960.Sign .01a .75cf = 26 (65 ), m = 14 64.869.99.861.6 1.562.6 1.3, .6?.4 2.8, 2.8?.8 399.0, 332.0?43.0 (n = 39) 9.5, 7.0?1.8 1.0, .0?.0 (n = 38) .0, .0?.0 (n = 39) 51.0, 49.0?2.0 (n = 36) 3.462.7 (n = 39) 5 (13) 13 (33) 1 (3) 4 (10)90.968.0 17.3610.4 1.1, .6?.5 2.8, 2.8?.0 425.0, 332.3?39.5 10.0, 8.0?2.0 3.5, 2.0?.0 (n = 84) 2.5, 1.0?.0 (n = 84) 43.0, 36.0?8.0 (n = 79) 4.463.2 (n = 84) 10 (12) 18 (21) 3 (3) 5 (6).00c .00c .58b .02b .52b .10b .00b .00b .00b .13c .89a .16a .77a .40ab cones who did not report dyskinesias (N = 64) (Mann-Whitney U tests, all p-values.0.24).Non-motor Symptoms in in Patients and ControlsCompared to controls, patients with PD displayed significantly higher mean scores on the HAD depression subscale (MannWhitney U = 1080.0, p,.001), the HAD anxiety subscale (MannWhitney U = 921.0, p,.01) as well as significantly lower scores on FACIT-fatigue (Mann-Whitney U = 451.5, p,.001), thus indicating more severe symptoms in the PD group. The SCOPA-sleep night scale did not differ significantly between the two groups (Student’s t = 1.45, p..15, ns). In the entire sample there were no significant gender differences in mean scores on FACIT or the HAD subscales (Mann-Whitney U tests, all p-values .0.14), thus making gender unlikely as a confounder in these analyses. Women had, however, significantly higher mean scores on SCOPA-S compared to men (Mann-Whitney U = 1485.0, p = .04). Subsequent ANCOVA with SCOPA-S as the dependent variable and gender and diagnose as fixed factors did not reveal any significant effect of patient/control on SCOPA-S scores when the effect of gender was controlled for (p..05, ns).U = 1499.0, p = .03) and TNF-a (Mann-Whitney U = 1466.0, p = .01) ?thus making gender a potential confounder in these two comparisons. ANCOVAS wer.